These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26399347)

  • 1. The malignant progression effects of regorafenib in human colon cancer cells.
    Tomida C; Aibara K; Yamagishi N; Yano C; Nagano H; Abe T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
    J Med Invest; 2015; 62(3-4):195-8. PubMed ID: 26399347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib induces adaptive resistance of colorectal cancer cells via inhibition of vascular endothelial growth factor receptor.
    Tomida C; Nagano H; Yamagishi N; Uchida T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
    J Med Invest; 2017; 64(3.4):262-265. PubMed ID: 28954993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic exposure of VEGF inhibitors promotes the malignant phenotype of colorectal cancer cells.
    Tomida C; Yamagishi N; Aibara K; Yano C; Uchida T; Abe T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
    J Med Invest; 2015; 62(1-2):75-9. PubMed ID: 25817288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGF pathway-targeting drugs induce evasive adaptation by activation of neuropilin-1/cMet in colon cancer cells.
    Tomida C; Yamagishi N; Nagano H; Uchida T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
    Int J Oncol; 2018 Apr; 52(4):1350-1362. PubMed ID: 29532881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic agent sunitinib induces epithelial to mesenchymal transition and accelerates motility of colorectal cancer cells.
    Tomida C; Yamagishi N; Nagano H; Uchida T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
    J Med Invest; 2017; 64(3.4):250-254. PubMed ID: 28954991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regorafenib as a potential adjuvant chemotherapy agent in disseminated small colon cancer: Drug selection outcome of a novel screening system using nanoimprinting 3-dimensional culture with HCT116-RFP cells.
    Yoshii Y; Furukawa T; Aoyama H; Adachi N; Zhang MR; Wakizaka H; Fujibayashi Y; Saga T
    Int J Oncol; 2016 Apr; 48(4):1477-84. PubMed ID: 26820693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells.
    Mirone G; Perna S; Shukla A; Marfe G
    J Cell Physiol; 2016 May; 231(5):1097-105. PubMed ID: 26419617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
    Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
    Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling.
    Cai MH; Xu XG; Yan SL; Sun Z; Ying Y; Wang BK; Tu YX
    J Exp Clin Cancer Res; 2018 Jul; 37(1):151. PubMed ID: 30005681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New molecular targeting drugs for metastatic colorectal cancer].
    Komatsu Y; Harada K; Fukushima H; Yuki S
    Nihon Rinsho; 2014 Jan; 72(1):120-6. PubMed ID: 24597359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New molecular-targeted agents for colorectal cancer - regorafenib and aflibercept].
    Kato S
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):6-9. PubMed ID: 23306912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1.
    Lippolis C; Refolo MG; D'Alessandro R; Carella N; Messa C; Cavallini A; Carr BI
    J Exp Clin Cancer Res; 2015 Sep; 34(1):90. PubMed ID: 26329608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of erythema multiforme induced by regorafenib therapy for metastatic colon cancer].
    Mii Y; Fukuoka E; Murata K; Otsubo D; Sawa H; Oka S; Iwatani Y; Kuroda D
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1841-3. PubMed ID: 25731348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Lysis Syndrome in Metastatic Colon Cancer Following Treatment with Regorafenib.
    Farooqi B; Simmons J; Hao Z
    J Gastrointest Cancer; 2015 Sep; 46(3):314-6. PubMed ID: 25859838
    [No Abstract]   [Full Text] [Related]  

  • 16. Endocrine gland-derived vascular endothelial growth factor strengthens cell invasion ability via prokineticin receptor 2 in colon cancer cell lines.
    Tabata S; Goi T; Nakazawa T; Kimura Y; Katayama K; Yamaguchi A
    Oncol Rep; 2013 Feb; 29(2):459-63. PubMed ID: 23135359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GDNF increases cell motility in human colon cancer through VEGF-VEGFR1 interaction.
    Huang SM; Chen TS; Chiu CM; Chang LK; Liao KF; Tan HM; Yeh WL; Chang GR; Wang MY; Lu DY
    Endocr Relat Cancer; 2014 Feb; 21(1):73-84. PubMed ID: 24165321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging VEGF-receptor inhibitors for colorectal cancer.
    Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
    Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib in metastatic colorectal cancer.
    Sartore-Bianchi A; Zeppellini A; Amatu A; Ricotta R; Bencardino K; Siena S
    Expert Rev Anticancer Ther; 2014 Mar; 14(3):255-65. PubMed ID: 24559322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.